- Home
- CURI vs KZIA Comparison
CURI vs KZIA Comparison
Compare CURI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURI | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 154.5M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CURI | KZIA |
|---|---|---|
| Price | $2.61 | $11.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.83 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.0M | 255.7K |
| Earning Date | 05-06-2026 | 06-04-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | ★ 54.17 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | $22.08 | ★ N/A |
| Revenue Growth | ★ 9.52 | N/A |
| 52 Week Low | $2.30 | $4.86 |
| 52 Week High | $5.51 | $17.40 |
Technical Indicators
Market Signals| Indicator | CURI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 42.77 |
| Support Level | $2.51 | $11.39 |
| Resistance Level | $2.95 | $14.85 |
| Average True Range (ATR) | 0.15 | 1.11 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 17.92 | 4.16 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.